and recommendation
Cytori Therapeutics, Inc. (CYTX)
Cytori Therapeutics, Inc. develops cellular therapeutics for specific diseases and medical conditions.
CYTX primarily provides Cytori Cell Therapy, which is in Phase III pivotal clinical trial for the treatment of impaired hand function in scleroderma.
CYTX offers Celution System devices, proprietary enzymes, and sterile consumable sets that are used at the point-of-therapeutic application or at an off-site processing center; and StemSource cell and tissue banking systems, as well as surgical accessories and instruments.
CYTX also provides ATI-0918, a liposomal encapsulation of doxorubicin for use in treating breast cancer, ovarian cancer, multiple myeloma, and Kaposi's sarcoma; and ATI-1123, a liposomal formulation of docetaxel for the treatment of non-small cell lung cancer, breast cancer, squamous cell carcinoma of the head and neck cancer, gastric adenocarcinoma, and hormone refractory prostate cancer.
The company was founded in 1996 and is headquartered in San Diego, California.
- May 5, 2015 - 10:15am | Financings
- April 23, 2015 - 8:20am | Out and About
- April 22, 2015 - 10:50am | BOD & C-Suite Updates
- April 13, 2015 - 9:31am | Regulatory
- April 7, 2015 - 8:59am | Regulatory
- April 6, 2015 - 8:21am | Regulatory
- March 18, 2015 - 8:08am | Financings
- February 26, 2015 - 9:08am | Regulatory
- February 24, 2015 - 8:32am | Regulatory
- February 17, 2015 - 8:23am | Regulatory
- January 12, 2015 - 9:19am | Regulatory
- December 19, 2014 - 9:18am | Out and About
- December 10, 2014 - 8:38am | Regulatory
- December 4, 2014 - 10:03am | Regulatory
- November 26, 2014 - 9:31am | Out and About
- November 21, 2014 - 9:38am | Research Notes
- November 19, 2014 - 7:34am | Research Notes
- November 14, 2014 - 1:58pm | Earnings
- November 14, 2014 - 8:43am | BOD & C-Suite Updates
- November 7, 2014 - 12:23pm | Earnings